2024
1620P Inherited variants in SRD5A genes and response to hormonal therapy in prostate cancer (SWOG S1216)
Ingles S, Pinski J, Manojlovic Z, Xiong S, Weisenberger D, Goldkorn A, Tangen C, McConkey D, Lara P, Hussain M, Quinn D, Thompson I, Lerner S, Dorff T, Agarwal N. 1620P Inherited variants in SRD5A genes and response to hormonal therapy in prostate cancer (SWOG S1216). Annals Of Oncology 2024, 35: s978. DOI: 10.1016/j.annonc.2024.08.1701.Peer-Reviewed Original ResearchEfficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin–Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial
Narayan V, Boorjian S, Alemozaffar M, Konety B, Shore N, Gomella L, Kamat A, Bivalacqua T, Montgomery J, Lerner S, Busby J, Poch M, Crispen P, Steinberg G, Schuckman A, Downs T, Mashni J, Lane B, Guzzo T, Bratslavsky G, Karsh L, Woods M, Brown G, Canter D, Luchey A, Lotan Y, Inman B, Williams M, Cookson M, Chang S, Sankin A, O’Donnell M, Sawutz D, Philipson R, Parker N, Yla-Herttuala S, Rehm D, Jakobsen J, Juul K, Dinney C. Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin–Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. Journal Of Urology 2024, 212: 74-86. PMID: 38704840, DOI: 10.1097/ju.0000000000004020.Peer-Reviewed Original ResearchConceptsNonmuscle-invasive bladder cancerPhase 3 trialBladder cancerFollow-upAdenoviral vector-based gene therapyProgression to muscle-invasive diseaseOpen-label phase 3 trialVector-based gene therapyCystectomy-free survivalMuscle-invasive diseaseMedian follow-upCarcinoma in situBladder preservationNadofaragene firadenovecOverall survivalGene therapyCytological assessmentTa/T1PatientsUS sitesCohortReceiving treatmentMonthsCancerHGRF
2023
Contemporary Role of Lymph Node Dissection in Genitourinary Cancers: Where Are We in 2023?
Myers A, Briganti A, Leibovich B, Lerner S, Moschini M, Rouprêt M, Shariat S, Spiess P, Stenzl A, Taneja S, Touijer K, Kamat A. Contemporary Role of Lymph Node Dissection in Genitourinary Cancers: Where Are We in 2023? European Urology Oncology 2023, 7: 412-420. PMID: 37980250, DOI: 10.1016/j.euo.2023.10.028.Peer-Reviewed Original ResearchLymph node dissectionNode dissectionPatient selectionGenitourinary cancersCurrent evidencePathologic nodal stageJudicious patient selectionAdjuvant treatmentNodal stageCollaborative reviewGenitourinary malignanciesTestis cancerTherapeutic benefitDissectionCancerLymphadenectomyLymphHighlight knowledge gapsReference standardContemporary evidenceOngoing areaCumulative benefitsEvidenceSurgeryPenile